Monday, March 30, 2026
Vitamin E dosing study in 200 adults with fatty liver disease completes trial
Photo by Annie Spratt / Unsplash

Vitamin E dosing study in 200 adults with fatty liver disease completes trial

Plain Language Summary
What this means for you:
A Vitamin E dose-finding study is complete, but its results on liver health are not yet available.

A recent study looked at whether different amounts of Vitamin E could help adults with nonalcoholic fatty liver disease (NAFLD). The trial involved 200 people across multiple medical centers. They were randomly assigned to take either a placebo (an inactive pill) or one of three Vitamin E doses (200 IU, 400 IU, or 800 IU) daily for 24 weeks. The main goal was to see how these doses changed a key liver blood test called ALT.

However, the results for this primary goal—how much ALT levels changed—have not been made public yet. The study also planned to follow people for 48 weeks, but we do not have those findings either. No information about side effects or how well people tolerated the different doses is available from this report.

The main reason to be careful is that without the results, we simply do not know if Vitamin E at any of these doses was helpful, had no effect, or could have caused problems for people with NAFLD. The study was sponsored by a U.S. government health institute, which is a sign of careful planning.

For now, readers should understand that this was a completed study designed to find the right dose, but the answers are not in yet. It does not provide evidence to start or stop taking Vitamin E for liver health. Patients should talk with their doctor about managing NAFLD based on currently proven treatments.

What this means for you:
A Vitamin E dose-finding study is complete, but its results on liver health are not yet available.
Read the Full Clinical Summary →
View Original Abstract ↓
Status: COMPLETED | Phase: PHASE2 Condition(s): Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis Intervention(s): Vitamin E (DRUG), Placebo (DRUG) This is a multicenter, randomized, double masked, placebo-controlled, parallel treatment groups dosing trial of Vitamin E in adult nonalcoholic fatty liver disease (NAFLD). Detailed: Adults age 18 years or older will be enrolled for 48 weeks and treated with 200 international units (IU), 400 IU, or 800 IU of Vitamin E or matching placebo for 24 weeks. The primary objective of the study is to determine the minimum effective dose of Vitamin E (d-alpha-tocopherol) based upon relative change in alanine aminotransferase (ALT) from baseline to 24 weeks. Primary Outcome(s): Relative Change in Alanine Aminotransferase (ALT) From Baseline to 24 Weeks Enrollment: 200 (ACTUAL) Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Start: 2022-08-05 | Primary Completion: 2025-03-04 Results posted: 2026-03-25